TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

Garassino, Marina Chiara; Martelli, Olga; Bettini, Anna; Floriani, Irene; Copreni, Elena; Lauricella, Calogero; Ganzinelli, Monica; Marabese, Mirko; Broggini, Massimo; Veronese, Silvio; Gherardi, Giorgio; Longo, Flavia; Fabbri, Maria Agnese; Tomirotti, M.; Alabiso, Oscar; Sarobba, Maria Giuseppa; Labianca, Roberto; Marsoni, Silvia; Farina, Gabriella; Scanni, A.

doi:10.1200/jco.2012.30.15_suppl.lba7501

Cited by 19 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…a,b), similar to previous reports comparing TKIs and chemotherapy in pretreated patients . However, a preliminary report from the TAILOR study favored chemotherapy in patients with wt‐ EGFR tumors . The observed higher ORR and the trend toward improved OS in patients with mut‐ EGFR tumors in the erlotinib arm support the predictive value of EGFR mutations for response to TKIs and their use in the first‐line setting .…”

Section: Discussionsupporting

confidence: 84%

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Karampeazis

Voutsina

Souglakos

et al. 2013

Cancer

100

View full text Add to dashboard Cite

BACKGROUND: In this superiority study, pemetrexed was compared with erlotinib in pre-treated patients with metastatic non-small cell lung cancer (NSCLC). METHODS: Patients with stage IIIB/IV NSCLC who progressed after first-line or second-line treatment were randomized to receive either pemetrexed or erlotinib. In total, 21.7% of patients in the pemetrexed arm and 23.5% of patients in the erlotinib arm had squamous cell histology, and treatment was third line in 39.2% and 46.4% of patients, respectively. The primary study endpoint was time to tumor progression (TTP). Epidermal growth factor receptor/v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (EGFR/KRAS) mutation status also was investigated. RESULTS: There was no difference in terms of the TTP (P 5.195), the objective response rate (P 5.469), or overall survival (P 5.986) between the 2 treatment arms. In patients who had squamous cell histology, erlotinib resulted in a superior TTP compared with pemetrexed (4.1 months vs 2.5 months, respectively; P 5.006). The incidence of grade 3 and 4 neutropenia, thrombocytopenia, and asthenia was significantly higher in the pemetrexed arm, whereas the incidence of grade 3 and 4 skin rash was higher in the erlotinib arm. CONCLUSIONS: Both pemetrexed and erlotinib had comparable efficacy in pre-treated patients with metastatic NSCLC, and the current results indicated that genotyping of tumor cells may have an important effect on treatment efficacy. Cancer 2013;119:2754-64.

show abstract

Section: Discussionsupporting

confidence: 84%

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Karampeazis

Voutsina

Souglakos

et al. 2013

Cancer

100

View full text Add to dashboard Cite

show abstract

“…OS has not yet been reported for this trial. 89 All three trials comparing second-or third-line therapy with BSC are included in a meta-analysis of published data. 90 The primary analysis was to compare the 1-year survival rate of active therapy with BSC.…”

Section: Targeted Therapy Together With Cytotoxic Chemotherapymentioning

confidence: 99%

Treatment of Stage IV Non-small Cell Lung Cancer

Socinski

Evans²,

Gettinger

et al. 2013

Chest

175

View full text Add to dashboard Cite

show abstract

“…The co-primary endpoint of the study, non-inferiority of gefitinib compared with docetaxel in OS, was observed [8]. Key trials comparing TKIs to placebo [5,22] and to chemotheraphy [8,[23][24][25] are summarized in Table 2.…”

Section: Egfr Tkismentioning

confidence: 99%

“…Patients with EGFR wildtype NSCLC have a response rate to EGFR TKI therapy of 1%-7%, a median PFS of approximately 2 months, and a median OS of 6 -8 months in retrospective subset analyses of second-line trials [24 -26]. Two recent prospective trials have demonstrated that in the second-line setting, PFS is inferior for patients with EGFR wild-type tumors treated with erlotinib compared with those treated with cytotoxic chemotherapy [25,27]. In one study, OS data are not yet available, and in the other trial, the results were similar between erlotinib and cytotoxic chemotherapy.…”

Section: Second-line Therapy For Patients With Egfr Wild-type Diseasementioning

confidence: 99%

Second-Line Therapy for Advanced NSCLC

Weiss

Stinchcombe

2013

The Oncologist

View full text Add to dashboard Cite

Most patients with lung cancer have non-small cell lung cancer (NSCLC) subtype and have advanced disease at the time of diagnosis. Improvements in both first-line and subsequent therapies are allowing longer survival and enhanced quality of life for these patients. The median overall survival observed in many second-line trials is approximately 9 months, and many patients receive further therapy after second-line therapy. The cytotoxic agents pemetrexed and docetaxel and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib are standard second-line therapies. For patients with EGFR mutation, a TKI is the favored second-line therapy if not already used in first-line therapy. For patients without the EGFR mutation, TKIs are an option, but many oncologists favor cytotoxic therapy. The inhibitor of the EML4/ALK fusion protein, crizotinib, has recently become a standard second-line treatment for patients with the gene rearrangement and has promise for patients with the ROS1 rearrangement. The Oncologist 2013;18:947-953Implications for Practice: The landscape of first-line treatment has generated challenges for clinical decisions in second-line therapy. For the patient treated with standard chemotherapy in the first line who has a treatable molecular change, this change should be targeted. More specifically, the patient with an epidermal growth factor receptor (EGFR) mutation should be treated with an EGFR tyrosine kinase inhibitor, and the patient with EML4/ALK rearrangement should be treated with crizotinib. However, these agents are increasingly being used in the first line, and most patients do not have these molecular changes. This leaves the clinician with many challenging questions regarding second-line therapy. How should the patient without treatable mutations be treated? Which clinical trials are most promising? How should the patient treated with a targeted agent in the first line be treated in the second line? This review addresses these issues, exploring the key existing data available to help guide informed clinical decisions. INTRODUCTIONLung cancer is the leading cause of cancer-related mortality in the United States and in the world [1,2]. Most patients have the non-small cell lung cancer (NSCLC) subtype and have advanced-stage disease at the time of diagnosis. The standard first-line therapy for advanced disease (defined as stage IIIB or IV) is a platinum doublet alone or with a targeted agent such as bevacizumab for four to six cycles [3]. Chemotherapy extends overall survival (OS), reduces disease-related symptoms, and improves quality of life (QoL). Historically, after completion of four to six cycles of platinum-based therapy, patients were observed, and at the time of radiographic or clinical evidence of disease progression, therapy was re-initiated. Approximately 30% of patients experience disease progression during firstline chemotherapy, and all patients with initial disease control will eventually experience disease progression and requ...

show abstract

TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR.

Cited by 19 publications

References 0 publications

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study

Treatment of Stage IV Non-small Cell Lung Cancer

Second-Line Therapy for Advanced NSCLC

Contact Info

Product

Resources

About